对于需持续应用胰岛素的广大糖尿病患，每天注射所用针头对于治疗效果和患者生活质量有着非常关键的影响，美享医药与天麦药业日前就日本泰尔茂株式会社34G针头签订商业合作协议，在合作市场内将目前人力可及的最细针头34G针头惠及广大糖尿病患。

For the diabetes patients using insulin, daily used needles has a critical influence on the treatment effect and the patients' quality of life. Maxmind has signed cooperation agreement with HTBT, one of the leading insulin technology and products provider in China, to bring the world’s smallest 34g needle manufacturer by Terumo Japan to China market to benefit the vast number of diabetic patients.

工欲善其事必先利其器，34G针头具备如下优势：
Advanced technology is premise to guarantee advanced quality. The Terumo 34G needle has the following advantages:


1）34G针头为目前世界最细针头（34G指一个平方米可以摆下多少根针）；
2）非对称柳叶刀尖更锐利；
3）双面锥形针管设计降低阻力；
4）只有4mm长的针头安全方便，更适应亚洲人的皮肤厚度。
5）实验数据证明的是针头注射后创面减少50% 创面大小直接影响皮下脂肪增生的多少（皮下脂肪增生表现为皮下结节)；
6）泰尔茂株式会社出品，获得日本产业设计振兴会的“グッドデザイン赏,”（Good Design Award）。

1) 34G needle is the world's smallest needle (34G refers to the number of needles can be placed in a square meter);
2) asymmetrical blade tip of willow leaf shape is more sharp;
3) designing of double-sided conical needle tube to reduce resistance;
4) only 4mm long needle is safe and convenient, which is more suitable for Asian skin thickness.
5) the experimental data proved that 50% reduction of wound size after needle injection directly affects the generation of subcutaneous fat hyperplasia (subcutaneous fat hyperplasia exists in form of subcutaneous nodules).
6) Manufactured by Terumo Japan, awarded Good Design Award by Japan Industry Design Revitalization association.

泰尔茂株式会社，（Terumo Corporation）成立于1921年，总部位于日本东京都涩谷区，是医疗器械及医药制品的大型企业。产品包括一次性医用器械，输血用具系列，医药品和营养药系列，血管造影与治疗导管，医用电子产品系列，人工心肺产品系列，输液泵，注射泵，输血泵，麻醉泵，靶控泵系列，检验产品系列，家庭医疗保健产品系列等。预计2018年营业收入达5970亿日元（合52亿美元）

Terumo Corporation, founded in 1921, headquartered in Shibuya district, Tokyo, Japan, is a large enterprise in medical equipment and pharmaceutical products. Products include disposable medical instruments, blood transfusion devices series, medical drugs and nutrition drugs series, angiography and treatment catheters, medical electronic products series, artificial heart and lung products series, infusion pumps, injection pumps, blood transfusion pumps, anesthesia pumps, target control pumps series, inspection products series, family health care products series. Expected 597 billion yen ($5.2 billion) of operating income in 2018.